皮质类固醇在转移性去势抵抗性前列腺癌治疗中作用的实用指南

Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer.

作者信息

De Santis Maria, Saad Fred

机构信息

University of Warwick, Cancer Research Unit, Coventry, UK; Queen Elizabeth Hospital, Birmingham, UK.

Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.

出版信息

Urology. 2016 Oct;96:156-164. doi: 10.1016/j.urology.2016.02.010. Epub 2016 Feb 18.

DOI:10.1016/j.urology.2016.02.010

PMID:26905032

Abstract

Corticosteroids have been used in combination with chemotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for more than three decades, particularly to treat pain, inflammation, and edema. More recently, they have been used in combination with hormonal agents. The importance of corticosteroids in mCRPC is due to their ability to manage adverse effects, reduce symptoms, and improve patients' quality of life. The appropriate selection of available options in mCRPC should be based on careful consideration of a patient's profile and comorbidities. This review provides an overview of the role of corticosteroids in treating mCRPC for the practicing urologist.

摘要

三十多年来，皮质类固醇一直与化疗联合用于治疗转移性去势抵抗性前列腺癌（mCRPC），特别是用于治疗疼痛、炎症和水肿。最近，它们已与激素药物联合使用。皮质类固醇在mCRPC中的重要性在于其能够管理不良反应、减轻症状并改善患者的生活质量。在mCRPC中选择合适的可用方案应基于对患者情况和合并症的仔细考虑。本综述为执业泌尿科医生概述了皮质类固醇在治疗mCRPC中的作用。